Docstoc

“Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)

Document Sample
“Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020) Powered By Docstoc
					Report Description & Highlights
With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential
that most analysts believe they will generate. This market, however, unlike small molecule generics, is
expected to be more akin to a marathon than a sprint. IMARC Group, one of the world‘s leading
research and advisory firms, in its new report “Biosimilar/Follow-on Biologics Market Report &
Forecast: A Focus on the US (2011-2020)” finds that biosimilars in the US will soon represent a multi-
billion dollar market as they would be posing stiff competition to as many as            twenty biological
molecules during 2011-2020.


Findings from the report suggest that the historical performance of Omnitrope cannot be taken as a
benchmark to gauge the potential of pipeline biosimilars as market acceptance for each biosimilar class
is expected to vary significantly from one another. The report expects that the competition between
branded biological drugs and their biosimilar counterparts would be more of a brand-brand competition
than a brand-generic competition. The high costs involved in the development and launch of biosimilars
are expected to limit the number of players in this market. As a result, erosions in price and volume
caused by biosimilars are likely to be lower compared to those created by small molecule generics.


IMARC‘s new report entitled “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on
the US (2011-2020)” provides an analytical and statistical insight into the US biosimilar market. The
study, that has been undertaken using desk-based as well as qualitative primary research, provides and
draws upon analysis of six aspects of the US biosimilar market.


Key Aspects Analyzed:


Evaluating the Current Market Landscape of Biosimilars:
         Identification of currently marketed biosimilars and their historical performance
         Identifying the reasons for the slow uptake of currently marketed biosimilars
         Analyzing historical data to formulate conclusions on the future growth and market trends of
         biosimilars


Evaluating the Extent of Price, Sales and Volume Erosions Caused by Biosimilars:
         Analyzing historical time series data on price, volume and sales erosion in the US & Europe
         Analyzing previous models and assumptions on price and volume erosion caused by biosimilars
         Evaluating and comparing price and volume erosion created by biosimilars vis-a-vis by small
         molecule generics
         Evaluating and comparing price, volume and sales erosion by biosimilars across various
         biological classes




imarc©
Evaluating the Market Potential of Biosimilars Across Various Molecules:
Molecules Covered: Somatropin (Genotropin/Humatrope/Other HGH), Epoetin Alfa (Epogen/Eprex),
Filgrastim (Neupogen), Pegfilgrastim (Neulasta), Insulin Lispro (Humalog), Insulin Glargine (Lantus),
Insulin Detemir (Levemir), Interferon Beta-1A (Avonex), Interferon Beta-1A (Rebif), Interferon Beta-1B
(Betaferon),   Bevacizumab        (Avastin),   Trastuzumab   (Herceptin),   Rituximab   (Mabthera/Rituxan),
Cetuximab (Erbitux), Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira), Ranibizumab
(Lucentis), Omalizumab (Xolair) and Natalizumab (Tysabri).


Focus of the Analysis for Each Molecule:
         Historical background and overview
         Historical brand sales
         Patent position
         Competing products
         Biosimilars in pipeline
         Brand and biosimilar sales forecasts


Evaluating the Sales of Biosimilars across Various Indications:
Indications Covered: Immunology & Inflammation, Diabetes, Oncology, Blood Disorders and Growth
Deficiency
Focus of the Analysis for Each Indication:
         Historical brand sales
         Brand and biosimilar sales forecasts
         Indication wise breakup of molecules


Evaluating the Biosimilar Competitive Landscape:
         Identifying branded biological manufacturers that expect the highest amount of erosion from
         biosimilars
         Identifying biosimilar manufacturers and their pipelines

Understanding the Current Legislation on Biosimilars:
         An insight into the Biologics Price Competition and Innovation Act
         An insight into the key biosimilar issues that still remain unaddressed
         Interchangeability and Substitutability
         Data Exclusivity
         Statutory provisions for dealing with patent litigations




imarc©
                                                                      Table of Contents


1         Market Definitions & Research Methodology ............................................................................................... 13
2         Executive Summary ........................................................................................................................................ 15
3         The US Biosimilar Market Landscape ........................................................................................................... 21
4         US Biosimilar Market: Current Experience ................................................................................................... 24
    4.1         The Performance of Growth Hormone Biosimilars Has Been Dismal So Far ............................................. 24
    4.2         Pediatrics Represent the Prime Customer Base for Growth Hormones ..................................................... 25
    4.3         Omnitrope Was Launched with an Inconvenient Delivery Device ............................................................... 25
    4.4         Prescribing Patterns for Omnitrope ............................................................................................................ 26
    4.5         Uptake is Likely to Increase with the Accumulation of Post-Market Safety Data ........................................ 26
5         US Biosimlar Market: How Much Price, Volume & Sales Erosion will Result ............................................ 28
    5.1         Omnitrope Cannot be Taken as a Benchmark to Gauge the Performance of Other Biosimilars ................ 28
    5.2         The European Uptake of ESA & GCSF Biosimilars Give Us a Very Positive Outlook for the US ............... 29
    5.3         Models for Biosimilar Volume Erosion Across Various Biological Classes ................................................. 32
    5.4         Models for Biosimilar Price Erosion Across Various Biological Classes ..................................................... 36
    5.5         Models for Biosimilar Sales Erosion Across Various Biological Classes .................................................... 40
6         US Biosimilar Market: Current Trends & Forecast by Drug ........................................................................ 41
    6.1      Growth Hormones ...................................................................................................................................... 44
       6.1.1      Somatropin (Genotropin/Humatrope/Other HGH) .............................................................................. 44
          6.1.1.1   Drug Overview ............................................................................................................................... 44
          6.1.1.2   Current Brand & Biosimilar Sales .................................................................................................. 45
          6.1.1.3   Brand & Biosimilar Forecast (2011-2020)...................................................................................... 47
    6.2      Erythropoiesis Stimulating Agents .............................................................................................................. 49
       6.2.1      Epoetin Alfa (Epogen/Eprex) ............................................................................................................. 49
          6.2.1.1    Drug Overview ............................................................................................................................... 49
          6.2.1.2    Historical Brand Sales ................................................................................................................... 50
          6.2.1.3    Brand & Biosimilar Forecast (2011-2020)...................................................................................... 51
    6.3      Granulocyte Colony Stimulating Factor ...................................................................................................... 54
       6.3.1      Filgrastim (Neupogen) ....................................................................................................................... 54
          6.3.1.1    Drug Overview ............................................................................................................................... 54
          6.3.1.2    Historical Brand Sales ................................................................................................................... 55
          6.3.1.3    Brand & Biosimilar Forecast (2011-2020)...................................................................................... 55
       6.3.2      Pegfilgrastim (Neulasta) ..................................................................................................................... 57
          6.3.2.1    Drug Overview ............................................................................................................................... 57
          6.3.2.2    Historical Brand Sales ................................................................................................................... 57
          6.3.2.3    Brand & Biosimilar Forecast (2011-2020)...................................................................................... 58
    6.4      Insulin ......................................................................................................................................................... 60
       6.4.1       Insulin Lispro (Humalog) .................................................................................................................... 60
          6.4.1.1      Drug Overview ............................................................................................................................... 60
          6.4.1.2      Historical Brand Sales ................................................................................................................... 60
          6.4.1.3      Brand & Biosimilar Forecast (2011-2020)...................................................................................... 61
       6.4.2       Insulin Glargine (Lantus) .................................................................................................................... 63
          6.4.2.1      Drug Overview ............................................................................................................................... 63
          6.4.2.2      Historical Brand Sales ................................................................................................................... 64
          6.4.2.3      Brand & Biosimilar Forecast (2011-2020)...................................................................................... 64
       6.4.3       Insulin Detemir (Levemir) ................................................................................................................... 66
          6.4.3.1      Drug Overview ............................................................................................................................... 66
          6.4.3.2      Historical Brand Sales ................................................................................................................... 66




imarc©
            6.4.3.3         Brand & Biosimilar Forecast (2011-2020)...................................................................................... 67
    6.5      Interferons .................................................................................................................................................. 69
       6.5.1       Interferon Beta-1A (Avonex) .............................................................................................................. 69
          6.5.1.1     Drug Overview ............................................................................................................................... 69
          6.5.1.2     Historical Brand Sales ................................................................................................................... 69
          6.5.1.3     Brand & Biosimilar Forecast (2011-2020)...................................................................................... 70
       6.5.2       Interferon Beta-1A (Rebif) .................................................................................................................. 72
          6.5.2.1     Drug Overview ............................................................................................................................... 72
          6.5.2.2     Historical Biosimilar Sales ............................................................................................................. 72
          6.5.2.3     Brand & Biosimilar Forecast (2011-2020)...................................................................................... 73
       6.5.3       Interferon Beta-1B (Betaferon/Betaseron) ......................................................................................... 75
          6.5.3.1     Drug Overview ............................................................................................................................... 75
          6.5.3.2     Historical Brand Sales ................................................................................................................... 75
          6.5.3.3     Brand & Biosimilar Forecast (2011-2020)...................................................................................... 76
    6.6      TNF Alpha & Monoclonal Antibodies (Immunology & Inflammation) .......................................................... 78
       6.6.1      Etanercept (Enbrel) ............................................................................................................................ 78
          6.6.1.1    Drug Overview ............................................................................................................................... 78
          6.6.1.2    Historical Brand Sales ................................................................................................................... 79
          6.6.1.3    Brand & Biosimilar Forecast (2011-2020)...................................................................................... 80
       6.6.2      Infliximab (Remicade) ........................................................................................................................ 82
          6.6.2.1    Drug Overview ............................................................................................................................... 82
          6.6.2.2    Historical Brand Sales ................................................................................................................... 83
          6.6.2.3    Brand & Biosimilar Forecast (2011-2020)...................................................................................... 83
       6.6.3      Adalimumab (Humira) ........................................................................................................................ 85
          6.6.3.1    Drug Overview ............................................................................................................................... 85
          6.6.3.2    Historical Brand Sales ................................................................................................................... 85
          6.6.3.3    Brand & Biosimilar Forecast (2011-2020)...................................................................................... 86
       6.6.4      Ranibizumab (Lucentis) ..................................................................................................................... 88
          6.6.4.1    Drug Overview ............................................................................................................................... 88
          6.6.4.2    Historical Brand Sales ................................................................................................................... 88
          6.6.4.3    Brand & Biosimilar Forecast (2011-2020)...................................................................................... 89
       6.6.5      Omalizumab (Xolair) .......................................................................................................................... 92
          6.6.5.1    Drug Overview ............................................................................................................................... 92
          6.6.5.2    Historical Brand Sales ................................................................................................................... 93
          6.6.5.3    Brand & Biosimilar Forecast (2011-2020)...................................................................................... 93
       6.6.6      Natalizumab (Tysabri) ........................................................................................................................ 95
          6.6.6.1    Drug Overview ............................................................................................................................... 95
          6.6.6.2    Historical Brand Sales ................................................................................................................... 96
          6.6.6.3    Brand & Biosimilar Forecast (2011-2020)...................................................................................... 97
    6.7      Monoclonal Antibodies (Oncology) ........................................................................................................... 100
       6.7.1      Bevacizumab (Avastin) .................................................................................................................... 100
          6.7.1.1    Drug Overview ............................................................................................................................. 100
          6.7.1.2    Historical Brand Sales ................................................................................................................. 101
          6.7.1.3    Brand & Biosimilar Forecast (2011-2020).................................................................................... 102
       6.7.2      Trastuzumab (Herceptin) ................................................................................................................. 104
          6.7.2.1    Drug Overview ............................................................................................................................. 104
          6.7.2.2    Historical Biosimilar Sales ........................................................................................................... 104
          6.7.2.3    Brand & Biosimilar Forecast (2011-2020).................................................................................... 105
       6.7.3      Rituximab (Mabthera) ...................................................................................................................... 107
          6.7.3.1    Drug Overview ............................................................................................................................. 107
          6.7.3.2    Historical Biosimilar Sales ........................................................................................................... 107
          6.7.3.3    Brand & Biosimilar Forecast (2011-2020).................................................................................... 108
       6.7.4      Cetuximab (Erbitux) ......................................................................................................................... 110
          6.7.4.1    Drug Overview ............................................................................................................................. 110
          6.7.4.2    Historical Brand Sales ................................................................................................................. 111
          6.7.4.3    Brand & Biosimilar Forecast (2011-2020).................................................................................... 111
7        US Biosimilar Market: Current Trends & Forecast by Indication .............................................................. 113
    7.1      Immunology & Inflammation ..................................................................................................................... 116
       7.1.1     Current Trends & Forecast .............................................................................................................. 116




imarc©
        7.1.2           Biosimilar Sales Breakup by Molecule ............................................................................................. 117
    7.2      Diabetes ................................................................................................................................................... 119
       7.2.1      Current Trends & Forecast .............................................................................................................. 119
       7.2.2      Biosimilar Sales Breakup by Molecule ............................................................................................. 120
    7.3      Oncology .................................................................................................................................................. 121
       7.3.1     Current Trends & Forecast .............................................................................................................. 121
       7.3.2     Biosimilar Sales Breakup by Molecule ............................................................................................. 122
    7.4      Blood Disorders ........................................................................................................................................ 124
       7.4.1      Current Trends & Forecast .............................................................................................................. 124
       7.4.2      Biosimilar Sales Breakup by Molecule ............................................................................................. 125
    7.5      Growth Deficiency .................................................................................................................................... 127
       7.5.1     Current Trends & Forecast .............................................................................................................. 127
       7.5.2     Biosimilar Sales Breakup by Molecule ............................................................................................. 128
8         Competitive Landscape ................................................................................................................................ 129
    8.1         Branded Manufacturers: Companies Facing the Highest Amount of Biosimilar Erosion .......................... 129
    8.2         Biosimilar Manufacturers: Companies Gaining the Most From Biosimilar Launches ................................ 132
9         Biosimilar Legislation in the US................................................................................................................... 136
    9.1         The Biologics Price Competition and Innovation Act: An Insight .............................................................. 136
    9.2         Biosimilar Issues that Still Remain Unaddressed ..................................................................................... 139
    9.3      Major Issues Impacting the Business Strategies of Biological Companies ............................................... 140
       9.3.1      Interchangeability & Substitutability ................................................................................................. 140
       9.3.2      Data Exclusivity................................................................................................................................ 141
       9.3.3      Patent Litigation ............................................................................................................................... 143
10        Key Company Profiles .................................................................................................................................. 145
    10.1        Teva Pharmaceutical Industries Ltd.......................................................................................................... 145
    10.2        Sandoz, Inc............................................................................................................................................... 146
    10.3        Hospira, Inc. ............................................................................................................................................. 147
    10.4        STADA Arzneimittel AG ............................................................................................................................ 148
    10.5        Dr. Reddy's Laboratories Ltd. ................................................................................................................... 149
    10.6        Celltrion, Inc.............................................................................................................................................. 150
    10.7        Bioexpress Therapeutics SA .................................................................................................................... 151




imarc©
List of Figures

Figure 1-1: Model Used to Forecast Brand and Biosimilar Sales ................................................................................. 14
Figure 2-1: US: Executive Summary: Biosimilar Timeline: 2011-2020 ......................................................................... 15
Figure 3-1: US: Biosimilar Market (in Million US$), 2007-2010 .................................................................................... 21
Figure 3-2: US: Biosimilar Timeline: 2011-2020 ........................................................................................................... 22
Figure 3-3: US: Biosimilar Market Forecast (in Million US$), 2011-2020 ..................................................................... 23
Figure 4-1: US: Human Growth Hormone Market: Sales Share of Different Brands & Biosimilars (in %), 2007-2010 . 24
Figure 4-2: US: Human Growth Hormone Market: Brand & Biosimilar Patient Share (in %), 2007-2020 ..................... 27
Figure 5-1: US, Germany, France, Italy, Spain & UK: Somatropin Biosimilars: Patient Share (in %), 2007-2010 ...... 29
Figure 5-2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010 ............ 30
Figure 5-3: US: Percentage of Physicians Expected to Prescribe ESA Biosimilars After They Have Been Launched,
(in %), 2010 .................................................................................................................................................................. 31
Figure 5-4: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010 ................ 31
Figure 5-5: Average Generic Volume Erosion of Molecules Based-on Complex Drug Characteristics, (in %) ............. 33
Figure 5-6: Average Generic Volume Erosion Across Various Countries From Time Since First Generic Entry, (in %)
..................................................................................................................................................................................... 35
Figure 5-7: Average Generic Price Erosion of Molecules Based Upon Complex Drug Characteristics, (in %) ............ 38
Figure 5-8: Average Generic Price Erosion Across Various Countries From Time Since First Generic Entry ............. 38
Figure 5-9: Average Brand Price Erosion Across Various Countries From Time Since First Generic Entry ................ 39
Figure 6-1: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Brand & Biosimilar Sales Share (in %),
2007-2010 .................................................................................................................................................................... 46
Figure 6-2: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Share of Marketed Brands & Biosimilars (in
%), 2007-2010.............................................................................................................................................................. 47
Figure 6-3: US: Somatropin (Genotropin/Humatrope/Other HGH) Market Forecast: Brand & Biosimilar Sales Share (in
%), 2011-2020.............................................................................................................................................................. 48
Figure 6-4: US: Epoetin Alfa (Epogen/Eprex) Market: Share of Marketed Brands (in %), 2007-2010.......................... 51
Figure 6-5: US: Epoetin Alfa (Epogen/Eprex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 . 53
Figure 6-6: US: Filgrastim (Neupogen) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ........... 56
Figure 6-7: US: Pegfilgrastim (Neulasta) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ......... 59
Figure 6-8: US: Insulin Lispro (Humalog) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ......... 62
Figure 6-9: US: Insulin Glargine (Lantus) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ......... 65
Figure 6-10: US: Insulin Detemir (Levemir) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ...... 68
Figure 6-11: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 . 71
Figure 6-12: US: Interferon Beta-1A (Rebif) Market: Brand & Biosimilar Sales Share (in %), 2011-2020 ................... 74
Figure 6-13: US: Interferon Beta-1B (Betaferon/Betaseron) Market Forecast: Brand & Biosimilar Sales Share (in %),
2011-2020 .................................................................................................................................................................... 77
Figure 6-14: US: Etanercept (Enbrel) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 .............. 81
Figure 6-15: US: Infliximab (Remicade) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ........... 84
Figure 6-16: US: Adalimumab (Humira) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 .......... 87
Figure 6-17: US: Ranibizumab (Lucentis) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ....... 91
Figure 6-18 : US: Omalizumab (Xolair) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ........... 94




imarc©
Figure 6-19: US: Natalizumab (Tysabri) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 .......... 99
Figure 6-20: US: Bevacizumab (Avastin) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ...... 103
Figure 6-21: US: Trastuzumab (Herceptin) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ... 106
Figure 6-22 : US: Rituximab (Mabthera) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ........ 109
Figure 6-23: US: Cetuximab (Erbitux) Market Forecast: Brand & Biosimilar Sales Share (in %), 2011-2020 ........... 112
Figure 7-1: US: Biosimilar Market Forecast: Share by Indication (in %), 2011-2020.................................................. 115
Figure 7-2: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Share (in %), 2011-2020 .......... 117
Figure 7-3: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-
2020 ........................................................................................................................................................................... 118
Figure 7-4: US: Diabetes Market forecast: Brand & Biosimilar Share (in %), 2011-2020 ........................................... 119
Figure 7-5: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020 ..................... 120
Figure 7-6: US: Oncology Market Forecast: Brand & Biosimilar Share (in %), 2011-2020......................................... 122
Figure 7-7: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020 .................... 123
Figure 7-8: US: Blood Disorder Market Forecast: Brand & Biosimilar Share (in %), 2011-2020 ................................ 125
Figure 7-9: US: Blood Disorder Biosimilar Market Forecast: Anemia & Neutropenia Sales (in %), 2011-2020.......... 125
Figure 7-10: US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in %), 2011-2020 ......... 126
Figure 7-11: US: Growth Deficiency Market: Brand & Biosimilar Share (in %), 2007-2010........................................ 127
Figure 7-12: US: Growth Deficiency Market Forecast: Brand & Biosimilar Share (in %), 2011-2020 ......................... 128
Figure 8-1: US: Innovator Company Brand Sales That Face Biosimilar Sales Erosion (in Million US$), 2010 & 2020
................................................................................................................................................................................... 131




imarc©
List of Tables


Table 1-1: US Biosimilar/Follow-On Biologics Market: Market Definition & Overview .................................................. 13
Table 2-1: US: Executive Summary: Major Biosimilar Launches ................................................................................. 16
Table 2-2: US: Executive Summary: Biosimilar Sales Forecast by Molecule (in Million US$), 2011-2020................... 18
Table 2-3: US: Executive Summary: Biosimilar Sales Forecast by Indication (in Million US$), 2011-2020.................. 19
Table 3-1: US: Patent Expiries and Biosimilar Launch ................................................................................................. 22
Table 5-1: Biosimilar Vulnerability of Various Biopharmaceutical Classes ................................................................... 28
Table 5-2: Germany, France, Italy, Spain & UK: Epoetin Alfa Biosimilars: Patient Share (in %), 2007-2010............... 30
Table 5-3: Germany, France, Italy, Spain & UK: Filgrastim Biosimilars: Patient Share (in %), 2008-2010 ................. 32
Table 5-4: US: Various Studies & Assumptions for Biosimilar Volume Erosion ........................................................... 33
Table 5-5: US, Germany and UK: Biosimilar Volume Penetration by Molecule After 3 years from Launch (in %) ....... 36
Table 5-6: Various Studies & Assumptions for Biosimilar Price Erosion ...................................................................... 37
Table 5-7: US, Germany and UK: Biosimilar Sales Penetration by Molecule After 3 years from Launch (in %) .......... 40
Table 6-1: US: Biosimilar Sales by Molecule (in Million US$), 2007-2010 ................................................................... 41
Table 6-2: US: Biosimilar Sales Forecast by Molecule (in Million US$), 2011-2020 .................................................... 42
Table 6-3: US: Biosimilar Share Forecast by Molecule (in %), 2011-2020................................................................... 43
Table 6-4: US: Somatropin: Brand & Biosimilar Market Overview ............................................................................... 45
Table 6-5: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Brand & Biosimilar Sales/Patient Share,
2007-2010 .................................................................................................................................................................... 46
Table 6-6: US: Somatropin (Genotropin/Humatrope/Other HGH) Market: Sales of Marketed Brands & Biosimilars (in
Million US$), 2007-2010............................................................................................................................................... 46
Table 6-7: US: Somatropin (Genotropin/Humatrope/Other HGH) Market Forecast: Brand & Biosimilar Sales/Patient
Share, 2011-2020 ........................................................................................................................................................ 48
Table 6-8: US: Epoetin Alfa: Brand & Biosimilar Market Overview............................................................................... 49
Table 6-9: US: Epoetin Alfa (Epogen/Eprex) Market: Brand Sales (in Millions US$), 2007-2010 ................................ 50
Table 6-10: US: Epoetin Alfa (Epogen/Eprex) Market: Sales of Marketed Brands (in Million US$), 2007-2010 .......... 50
Table 6-11: US: Epoetin Alfa (Epogen/Eprex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020
..................................................................................................................................................................................... 52
Table 6-12: US: Filgrastim: Brand & Biosimilar Market Overview ................................................................................ 54
Table 6-13: US: Filgrastim (Neupogen) Market: Brand Sales (in Millions US$), 2007-2010 ........................................ 55
Table 6-14: US: Filgrastim (Neupogen) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 ......... 56
Table 6-15: US: Pegfilgrastim: Brand & Biosimilar Market Overview ........................................................................... 57
Table 6-16: US: Pegfilgrastim (Neulasta) Market: Brand Sales (in Millions US$), 2007-2010 ..................................... 58
Table 6-17: US: Pegfilgrastim (Neulasta) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 ....... 58
Table 6-18: US: Insulin Lispro: Brand & Biosimilar Market Overview ........................................................................... 60
Table 6-19: US: Insulin Lispro (Humalog) Market: Brand Sales (in Millions US$), 2007-2010 ..................................... 61
Table 6-20: US: Insulin Lispro (Humalog) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 ...... 62
Table 6-21: US: Insulin Glargine: Brand & Biosimilar Market Overview ....................................................................... 63
Table 6-22: US: Insulin Glargine (Lantus) Market: Brand Sales (in Millions US$), 2007-2010..................................... 64
Table 6-23: US: Insulin Glargine (Lantus) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 ..... 65




imarc©
Table 6-24: US: Insulin Detemir: Brand & Biosimilar Market Overview ........................................................................ 66
Table 6-25: US: Insulin Detemir (Levemir) Market: Brand Sales (in Millions US$), 2007-2010 ................................... 67
Table 6-26: US: Insulin Detemir (Levemir) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 .... 68
Table 6-27: US: Interferon Beta-1A (Avonex): Brand & Biosimilar Market Overview ................................................... 69
Table 6-28: US: Interferon Beta-1A (Avonex) Market: Brand Sales (in Millions US$), 2007-2010 .............................. 70
Table 6-29: US: Interferon Beta-1A (Avonex) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 . 71
Table 6-30: US: Interferon Beta-1A (Rebif): Brand & Biosimilar Market Overview ....................................................... 72
Table 6-31: US: Interferon Beta-1A (Rebif) Market: Brand Sales (in Millions US$), 2007-2010 ................................... 73
Table 6-32: US: Interferon Beta-1A (Rebif) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 .... 73
Table 6-33: US: Interferon Beta-1B: Brand & Biosimilar Market Overview ................................................................... 75
Table 6-34: US: Interferon Beta-1B (Betaferon/Betaseron) Market: Brand Sales (in Millions US$), 2007-2010 ......... 76
Table 6-35: US: Interferon Beta-1B (Betaferon/Betaseron) Market Forecast: Brand & Biosimilar Sales/Patient Share,
2011-2020 .................................................................................................................................................................... 76
Table 6-36: US: Etanercept: Brand & Biosimilar Market Overview............................................................................... 79
Table 6-37: US: Etanercept (Enbrel) Market: Brand Sales (in Millions US$), 2007-2010............................................. 79
Table 6-38: US: Etanercept (Enbrel) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 ............. 80
Table 6-39: US: Infliximab: Brand & Biosimilar Market Overview ................................................................................ 82
Table 6-40: US: Infliximab (Remicade) Market: Brand Sales (in Millions US$), 2007-2010 ......................................... 83
Table 6-41: US: Infliximab (Remicade) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020........... 84
Table 6-42: US: Adalimumab: Brand & Biosimilar Market Overview ............................................................................ 85
Table 6-43: US: Adalimumab (Humira) Market: Brand Sales (in Millions US$), 2007-2010 ........................................ 86
Table 6-44: US: Adalimumab (Humira) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 .......... 87
Table 6-45: US: Ranibizumab: Brand & Biosimilar Market Overview ........................................................................... 88
Table 6-46: US: Ranibizumab (Lucentis) Market: Brand Sales (in Million US$), 2007-2010 ........................................ 89
Table 6-47: US: Ranibizumab (Lucentis) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020....... 90
Table 6-48: US: Omalizumab: Brand & Biosimilar Market Overview ............................................................................ 92
Table 6-49: US: Omalizumab (Xolair) Market: Brand Sales (in Millions US$), 2007-2010 ........................................... 93
Table 6-50: US: Omalizumab (Xolair) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 ............ 94
Table 6-51: US: Natalizumab: Brand & Biosimilar Market Overview ............................................................................ 95
Table 6-52: US: Natalizumab (Tysabri) Market: Brand Sales (in Millions US$), 2007-2010......................................... 96
Table 6-53: US: Natalizumab (Tysabri) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 ......... 98
Table 6-54: US: Bevacizumab: Brand & Biosimilar Market Overview ........................................................................ 100
Table 6-55: US: Bevacizumab (Avastin) Market: Brand Sales (in Millions US$), 2007-2010 .................................... 101
Table 6-56: US: Bevacizumab (Avastin) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020....... 102
Table 6-57: US: Trastuzumab: Brand & Biosimilar Market Overview ......................................................................... 104
Table 6-58: US: Trastuzumab (Herceptin) Market: Brand Sales (in Millions US$), 2007-2010 ................................. 105
Table 6-59: US: Trastuzumab (Herceptin) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 .... 106
Table 6-60: US: Rituximab: Brand & Biosimilar Market Overview ............................................................................. 107
Table 6-61: US: Rituximab (Mabthera) Market: Brand Sales (in Millions US$), 2007-2010 ....................................... 108
Table 6-62: US: Rituximab (Mabthera) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 ........ 109
Table 6-63: US: Cetuximab: Brand & Biosimilar Market Overview ............................................................................. 110
Table 6-64: US: Cetuximab (Erbitux) Market: Brand Sales (in Millions US$), 2007-2010 .......................................... 111



imarc©
Table 6-65: US: Cetuximab (Erbitux) Market Forecast: Brand & Biosimilar Sales/Patient Share, 2011-2020 ........... 112
Table 7-1: US: Biosimilars Market: Indications Assigned for Various Molecules ........................................................ 113
Table 7-2: US: Biosimilars Market: Sales by Indication (in Million US$), 2007-2010.................................................. 114
Table 7-3: US: Biosimilar Market Forecast: Sales by Indication (in Million US$), 2011-2020 ................................... 114
Table 7-4: US: Immunology & Inflammation Market: Brand Sales (in Million US$), 2007-2010 ................................. 116
Table 7-5: US: Immunology & Inflammation Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020
................................................................................................................................................................................... 116
Table 7-6: US: Immunology & Inflammation Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$),
2011-2020 .................................................................................................................................................................. 118
Table 7-7: US: Diabetes Market: Brand Sales (in Million US$), 2007-2010 ............................................................... 119
Table 7-8: US: Diabetes Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020 ............................ 119
Table 7-9: US: Diabetes Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020 ....... 120
Table 7-10: US: Oncology Market: Brand Sales (in Million US$), 2007-2010 ............................................................ 121
Table 7-11: US: Oncology Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020 ......................... 121
Table 7-12: US: Oncology Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020 .... 122
Table 7-13 : US: Blood Disorder Market: Brand Sales (in Million US$), 2007-2010 ................................................... 124
Table 7-14 : US: Blood Disorder Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020 ................ 124
Table 7-15 : US: Blood Disorder Market Forecast: Biosimilar Sales Breakup by Molecule (in Million US$), 2011-2020
................................................................................................................................................................................... 126
Table 7-16 : US: Growth Deficiency Market: Brand & Biosimilar Sales (in Million US$), 2007-2010.......................... 127
Table 7-17 : US: Growth Deficiency Market Forecast: Brand & Biosimilar Sales (in Million US$), 2011-2020........... 127
Table 8-1: US: Innovator Companies Facing the Highest Amount of Biosimilar Sales Erosion (in Million US$), 2010,
2013, 2016 & 2020 ..................................................................................................................................................... 130
Table 8-2: Companies Developing Herceptin (Trastuzumab) Biosimilars .................................................................. 132
Table 8-3: Companies Developing Enbrel (Etanercept) Biosimilars ........................................................................... 133
Table 8-4: Companies Developing Remicade (Infliximab) Biosimilars ....................................................................... 133
Table 8-5: Companies Developing Mabthera (Rituximab) Biosimilars ....................................................................... 134
Table 8-6: Companies Developing Humira (Trastuzumab) Biosimilars ...................................................................... 134
Table 8-7: Companies Developing Other Biosimilars ................................................................................................. 135
Table 9-1: US: Overview of Biosimilar Legislations .................................................................................................... 136
Table 9-2: Comparison of Patent Protection and Data Exclusivity ............................................................................. 143




imarc©
Prices and Order Information




  Single user license      Single user license       Single user license    Multiple user license
         PDF                    CD ROM                   Hard Copy              All Formats

       US$ 1200                 US$ 1600                  US$ 1600               US$ 1900




I would like to order the market study “Biosimilar/Follow-on Biologics Market Report & Forecast: A
Focus on the US (2011-2020)”




 Kindly Complete Your Details


Your Name:

Job Title:

Company:

Email Id:

Telephone Number:

Adress:


 Contact IMARC Group


Krishna Sharma
International Market Research Analysis and Consulting Group


       : +91-11-4256531 (Asia), +1-631-791-1145 (North America)

       : sales@imarcgroup.com
About IMARC
For more than 5 years, the International Market Analysis Research and Consulting Group has
been a leading advisor on management strategy and market research worldwide. We partner
with clients in all sectors and regions to identify their highest-value opportunities, address their
most critical challenges, and transform their businesses.


IMARC's information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company's expertise.


IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.




Imarc©

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:73
posted:12/7/2011
language:English
pages:13
Description: With sales worth US$ 57 Million in 2010, biosimilars are still far from their billion dollar sales potential that most analysts believe they will generate. This market, however, unlike small molecule generics, is expected to be more akin to a marathon than a sprint. IMARC Group, one of the world‘s leading research and advisory firms, in its new report “Biosimilar/Follow-on Biologics Market Report & Forecast: A Focus on the US (2011-2020)” finds that biosimilars in the US will soon represent a multi-billion dollar market as they would be posing stiff competition to as many as twenty biological molecules during 2011-2020.